Cited 2 times in
In Vivo Evaluation of Commercially Available Gel-Type Polyethylene Glycol Membrane for Carrier of Recombinant Human Bone Morphogenetic Protein-2
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김창성 | - |
dc.contributor.author | 이중석 | - |
dc.contributor.author | 정의원 | - |
dc.contributor.author | 조규성 | - |
dc.date.accessioned | 2017-11-02T08:06:55Z | - |
dc.date.available | 2017-11-02T08:06:55Z | - |
dc.date.issued | 2017 | - |
dc.identifier.issn | 0278-2391 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/154095 | - |
dc.description.abstract | PURPOSE: This study evaluated a commercially available, 3-dimensional gel-type polyethylene glycol (PEG) membrane as a carrier for recombinant human bone morphogenetic protein-2 (rhBMP-2) using a rat calvarial defect model. Another gel-type carrier, fibrin-fibronectin system (FFS), was used as a positive control. MATERIALS AND METHODS: Critical-size defects were made in the rat calvarium, which were allocated to 1 of 10 groups comprising 2 healing periods and biomaterial conditions: 1) sham control, 2) FFS only, 3) FFS plus BMP-2, 4) PEG only, and 5) PEG plus BMP-2. Radiographic and histologic analyses were performed at 2 and 8 weeks after surgery. RESULTS: After 2 weeks, some parts of the FFS were biodegraded and extensive cellular infiltration was observed at sites that received FFS or FFS plus BMP-2. The PEG membrane retained its augmented volume without cellular infiltration at sites that received PEG or PEG plus BMP-2. After 8 weeks, the FFS was completely degraded and replaced by new bone and connective tissues. In contrast, the volume of residual PEG was similar to that at 2 weeks, with slight cellular infiltration. In particular, there was progressive bone regeneration around micro-cracks and resorbed outer surface in the PEG + BMP-2 group. Although the PEG + BMP-2 group showed increased area and percentage of new bone, there was no statistical relevance after 2 and 8 weeks in histomorphometric analyses. However, the appearance of the healing differed (with new bone formation along micro-cracks in the PEG + BMP-2 group), and further studies with longer healing periods are needed to draw conclusions about clinical applications. CONCLUSION: Evidence of mechanical stability and new bone formation along micro-cracks when using PEG plus BMP-2 might support the PEG membrane as a candidate carrier material for rhBMP-2. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | W.B. Saunders Co. | - |
dc.relation.isPartOf | JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Animals | - |
dc.subject.MESH | Bone Development/drug effects | - |
dc.subject.MESH | Bone Morphogenetic Protein 2/administration & dosage* | - |
dc.subject.MESH | Drug Carriers/administration & dosage* | - |
dc.subject.MESH | Gels/administration & dosage | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Membranes, Artificial | - |
dc.subject.MESH | Polyethylene Glycols/administration & dosage* | - |
dc.subject.MESH | Rats | - |
dc.subject.MESH | Rats, Sprague-Dawley | - |
dc.subject.MESH | Recombinant Proteins/administration & dosage | - |
dc.subject.MESH | Skull/diagnostic imaging | - |
dc.subject.MESH | Skull/drug effects | - |
dc.subject.MESH | Skull/growth & development | - |
dc.subject.MESH | Skull/injuries* | - |
dc.subject.MESH | Transforming Growth Factor beta/administration & dosage* | - |
dc.subject.MESH | X-Ray Microtomography | - |
dc.title | In Vivo Evaluation of Commercially Available Gel-Type Polyethylene Glycol Membrane for Carrier of Recombinant Human Bone Morphogenetic Protein-2 | - |
dc.type | Article | - |
dc.publisher.location | United States | - |
dc.contributor.college | College of Dentistry | - |
dc.contributor.department | Dept. of Periodontology | - |
dc.contributor.googleauthor | Ji-Woong Jang | - |
dc.contributor.googleauthor | Jung-Seok Lee | - |
dc.contributor.googleauthor | Ui-Won Jung | - |
dc.contributor.googleauthor | Chang-Sung Kim | - |
dc.contributor.googleauthor | Kyoo-Sung Cho | - |
dc.identifier.doi | 10.1016/j.joms.2016.05.004 | - |
dc.contributor.localId | A03185 | - |
dc.contributor.localId | A03692 | - |
dc.contributor.localId | A03810 | - |
dc.contributor.localId | A01041 | - |
dc.relation.journalcode | J01659 | - |
dc.identifier.eissn | 1531-5053 | - |
dc.identifier.pmid | 27288839 | - |
dc.identifier.url | http://www.sciencedirect.com/science/article/pii/S0278239116301495 | - |
dc.contributor.alternativeName | Kim, Chang Sung | - |
dc.contributor.alternativeName | Lee, Jung Seok | - |
dc.contributor.alternativeName | Jung, Ui Won | - |
dc.contributor.alternativeName | Cho, Kyoo Sung | - |
dc.contributor.affiliatedAuthor | Lee, Jung Seok | - |
dc.contributor.affiliatedAuthor | Jung, Ui Won | - |
dc.contributor.affiliatedAuthor | Cho, Kyoo Sung | - |
dc.contributor.affiliatedAuthor | Kim, Chang Sung | - |
dc.citation.title | Journal of Oral and Maxillofacial Surgery | - |
dc.citation.volume | 75 | - |
dc.citation.number | 297 | - |
dc.citation.startPage | 1 | - |
dc.citation.endPage | 13 | - |
dc.identifier.bibliographicCitation | JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY, Vol.75(297) : 1-13, 2017 | - |
dc.date.modified | 2017-11-01 | - |
dc.identifier.rimsid | 41591 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.